Download PDF
Hamostaseologie 2019; 39(04): 360-367
DOI: 10.1055/s-0039-1698810
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years

Sabine Friederike Karolin Kittler
1   Biotest AG, Dreieich, Germany
,
Wolfgang Miesbach
2   Hemophilia Center, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt/Main, Germany
,
Artur Bauhofer
1   Biotest AG, Dreieich, Germany
,
Thomas Becker
1   Biotest AG, Dreieich, Germany
,
Jörg Schüttrumpf
1   Biotest AG, Dreieich, Germany
,
Patrick Dubovy
1   Biotest AG, Dreieich, Germany
,
László Nemes
3   National Hemophilia Center and Hemostasis Department, Medical Center, Hungarian Defence Forces, Budapest, Hungary
,
Heinrich Richter
4   Coagulation Center Muenster, Muenster, Germany
,
Christoph Königs
5   Department of Pediatrics, Hemophilia Center, Goethe University, University Hospital Frankfurt, Frankfurt/Main, Germany
› Author Affiliations Funding This work was funded by Biotest AG. S.F.K.K, A.B., J.S., and T.B. are employees of Biotest AG. W.M. receives grants and personal fees for lectures and consultancy from Biotest, Bayer, Biogen Idec, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, Sobi, and UniQure. L.N. receives personal fees for lectures, organizing education, and consultancy from Bayer, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and Sobi. H.R. receives grants, travel expenses, and/or personal fees for lectures and consultancy from Biotest, Bayer, Chugai/Roche, CSL Behring, Novo Nordisk, Pfizer, Sobi, and Takeda. C.K. and his institution received funding or personal fees from Bayer, Biotest, CSL Behring, Gilead, Intersero, Jansen, Novo Nordisk, Pfizer, Roche, Shire, Sobi, and the Federal Ministry of Education and Research and the EU (IMI, FP7).
Further Information

Publication History

26 February 2019

21 August 2019

Publication Date:
24 October 2019 (online)

Also available at
   Permissions and Reprints

Abstract

We describe the results of the (to our knowledge) longest long-term noninterventional study so far performed to obtain real-life data on the treatment of hemophilia A patients with a single plasma-derived FVIII concentrate containing von Willebrand factor (pdFVIII; Haemoctin/Faktor VIII SDH Intersero). A total of 198 patients (146 in Germany and 52 in Hungary), of whom 160 had severe and 38 nonsevere hemophilia A, representing all age groups (0–88 years; mean ∼25 years at inclusion) were analyzed during prophylactic or on-demand treatment over 18 years (overall 1,418 patient-years; mean >7 years). pdFVIII was very effective and well tolerated. The mean annual bleeding rate, including spontaneous and traumatic bleeds, was considerably lower for patients treated prophylactically (mean 5.4; median 3.1) than for patients treated on demand (mean 26.1; median 21.9). Inhibitors were found in 13% (3/23) and high-titer inhibitors in 4% (1/23) of previously untreated patients with severe hemophilia A. Four previously treated patients with severe hemophilia A developed inhibitors, thereof three high-titer inhibitors (3.3 and 2.5 high-titer inhibitors in 1,000 patient-years). No unexpected adverse effect on the health of the patients, no pdFVIII-related thrombosis, thromboembolic event, or hypersensitivity reaction, and no suspected viral transmission related to pdFVIII were documented.

Zusammenfassung

Wir berichten über die Ergebnisse der unseres Wissens längsten nicht-interventionellen Langzeitstudie mit einem von-Willebrand-Faktor-haltigem humanen FVIII-Konzentrat (pdFVIII, Haemoctin®/Faktor VIII SDH Intersero®) zur Erfassung praxisnaher Daten aus der alltäglichen Therapie von Patienten mit einer Hämophilie A. 198 Patienten (146 in Deutschland und 52 in Ungarn) aller Altersgruppen (0–88 Jahre; durchschnittlich ∼25 Jahre alt beim Einschluss), 160 davon mit schwerer und 38 mit nicht schwerer Hämophilie A, wurden im Rahmen ihrer prophylaktischen oder Bedarfstherapie über 18 Jahre analysiert (insgesamt 1418 Patientenjahre; durchschnittlich >7 Jahre). Der pdFVIII erwies sich als sehr wirksam und verträglich. Die durchschnittliche jährliche Blutungsrate (spontane und traumatische Blutungen) war deutlich geringer in Patienten, die prophylaktisch (Mittelwert 5,4; Median 3,1) anstatt bei Bedarf (Mittelwert 26,1; Median 21,9) mit pdFVIII behandelt wurden. Inhibitoren wurden in 13% (3/23) und hochtitrige in 4% (1/23) der zuvor unbehandelten Patienten mit schwerer Hämophilie A dokumentiert. Vier der vorbehandelten Patienten mit schwerer Hämophilie A entwickelten Inhibitoren, 3 davon hochtitrige (3.3 Inhibitoren und 2.5 hochtitrige pro 1000 Patientenjahren). Während der Langzeittherapie mit pdFVIII wurde kein unerwünschter Einfluss auf den allgemeinen Gesundheitszustand der Patienten festgestellt. Es trat keine thromboembolische Reaktion, keine Überempfindlichkeitsreaktion, und keine Virusübertragung im kausalen Zusammenhang mit pdFVIII auf.

Keywords

hemophilia A - plasma-derived factor VIII - FVIII inhibitor - noninterventional study

Schlüsselwörter

Hämophilie A - plasmatischer Faktor VIII - FVIII Inhibitor - nicht-interventionelle Studie

Authors' Contributions

L.N. and C.K. contributed with a significant number of patients to this NIS. A.B. and T.B. designed the Biotest NIS. A.B., J.S., T.B., and S.F.K.K. performed the research. P.D. was responsible for data management and provided statistical support. S.F.K.K., A.B., T.B., and J.S. analyzed the data. The main writing was done by S.F.K.K. Analyses were discussed with W.M., C.K., H.R., and L.N.

All authors reviewed and approved the final manuscript.


Supplementary Material

 

  • References

  • 1 Miesbach W, O'Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019; 25 (04) 545-557
    PubMedGoogle Scholar
  • 2 Weyand AC, Pipe SW. New therapies for hemophilia. Blood 2019; 133 (05) 389-398
    CrossrefPubMedGoogle Scholar
  • 3 van den Berg HM. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors. Haemophilia 2014; 20 (04) (Suppl. 04) 76-79
    CrossrefPubMedGoogle Scholar
  • 4 Peyvandi F, Mannucci PM, Palla R, Rosendaal FR. SIPPET: methodology, analysis and generalizability. Haemophilia 2017; 23 (03) 353-361
    CrossrefPubMedGoogle Scholar
  • 5 Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11 (09) 1655-1662
    CrossrefPubMedGoogle Scholar
  • 6 Hay CR, Palmer B, Chalmers E. , et al; United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117 (23) 6367-6370
    CrossrefPubMedGoogle Scholar
  • 7 van Velzen AS, Eckhardt CL, Peters M. , et al. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study. J Thromb Haemost 2017; 15 (07) 1422-1429
    CrossrefPubMedGoogle Scholar
  • 8 CHMP. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009 rev 2. 2018 . Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-revision-2_en.pdf . Accessed September 25, 2019
    PubMedGoogle Scholar
  • 9 Nemes L, Pollmann H, Becker T. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A. Haemophilia 2012; 18 (04) 496-502
    CrossrefPubMedGoogle Scholar
  • 10 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
    CrossrefPubMedGoogle Scholar
  • 11 Calvez T, Chambost H, d'Oiron R. , et al. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica 2018; 103 (01) 179-189
    CrossrefPubMedGoogle Scholar
  • 12 Gouw SC, van den Berg HM, Fischer K. , et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121 (20) 4046-4055
    CrossrefPubMedGoogle Scholar
  • 13 Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5 (07) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 14 Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost 2011; 9 (10) 1948-1958
    CrossrefPubMedGoogle Scholar
  • 15 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
    CrossrefPubMedGoogle Scholar
  • 16 Sharathkumar A, Lillicrap D, Blanchette VS. , et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1 (06) 1228-1236
    CrossrefPubMedGoogle Scholar
  • 17 ter Avest PC, Fischer K, Mancuso ME. , et al; CANAL Study Group. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 2008; 6 (12) 2048-2054
    CrossrefPubMedGoogle Scholar
  • 18 Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence?. Haemophilia 2013; 19 (01) (Suppl. 01) 2-7
    PubMedGoogle Scholar
  • 19 Matzinger P. The danger model: a renewed sense of self. Science 2002; 296 (5566): 301-305
    CrossrefPubMedGoogle Scholar
  • 20 Santagostino E, Mancuso ME, Rocino A. , et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130 (03) 422-427
    CrossrefPubMedGoogle Scholar
  • 21 Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113 (03) 600-603
    CrossrefPubMedGoogle Scholar
  • 22 Peyvandi F, Mannucci PM, Garagiola I. , et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 23 Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F. , SIPPET Study Group. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood 2017; 130 (15) 1757-1759
    CrossrefPubMedGoogle Scholar
  • 24 Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008; 14 (03) (Suppl. 03) 36-42
    PubMedGoogle Scholar
  • 25 Gomez K, Klamroth R, Mahlangu J, Mancuso ME, Mingot ME, Ozelo MC. Key issues in inhibitor management in patients with haemophilia. Blood Transfus 2014; 12 (01) (Suppl. 01) s319-s329
    PubMedGoogle Scholar
  • 26 Ragni MV, Ojeifo O, Feng J. , et al; Hemophilia Inhibitor Study. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia 2009; 15 (05) 1074-1082
    CrossrefPubMedGoogle Scholar
  • 27 Collins PW, Chalmers E, Hart DP. , et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160 (02) 153-170
    CrossrefPubMedGoogle Scholar
  • 28 Klamroth R, Holzhauer S, Zimmermann R, Heller C, Kurnik K. , Beriate® Pharmacovigilance Group. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study. Thromb Res 2014; 134 (Suppl. 01) S16-S21
    CrossrefPubMedGoogle Scholar
  • 29 Manco-Johnson MJ, Kempton CL, Reding MT. , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11 (06) 1119-1127
    CrossrefPubMedGoogle Scholar
  • 30 Li C, Zhang X, Zhao Y. , et al. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study. Curr Med Res Opin 2017; 33 (07) 1223-1230
    CrossrefPubMedGoogle Scholar
  • 31 Zhao Y, Xiao J, Yang R. , et al. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatr Hematol Oncol 2017; 34 (03) 138-148
    PubMedGoogle Scholar
  • 32 European Medicines Agency. Report of expert meeting on factor VIII products and inhibitor development 2007. Available at: https://www.ema.europa.eu/en/documents/report/report-expert-meeting-factor-viii-products-inhibitor-development_en.pdf . Accessed September 25, 2019
    PubMed
  • 33 Franchini M, Frattini F, Crestani S, Bonfanti C. Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors. Hematology 2013; 18 (04) 183-190
    CrossrefPubMedGoogle Scholar
  • 34 Schwarz J, Astermark J, Menius ED. , et al; Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia 2013; 19 (01) 113-118
    CrossrefPubMedGoogle Scholar
  • 35 Marcucci M, Mancuso ME, Santagostino E. , et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost 2015; 113 (05) 958-967
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Lebreton A, Castet S, Falaise C, Rugeri L, Schved JF, Wibaut B. After the SIPPET study: position paper of the CoMETH, the French society of haemophilia. Haemophilia 2018; 24 (02) e55-e57
    CrossrefPubMedGoogle Scholar
  • 37 van den Berg HM, Gouw SC, van der Bom JG. Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med 2013; 368 (15) 1457
    CrossrefPubMedGoogle Scholar
  • 38 Klukowska A, Komrska V, Vdovin V. , et al. Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate® : Final report from a prospective study. Haemophilia 2018; 24 (02) 221-228
    CrossrefPubMedGoogle Scholar
  • 39 Fischer K, Lassila R, Peyvandi F. , et al; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113 (05) 968-975
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4 (12) 2576-2581
    CrossrefPubMedGoogle Scholar